Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 105940582 | 10594058 | 2 | F | 20140916 | 20160817 | 20141119 | 20160825 | EXP | PHHY2014DE151325 | NOVARTIS | 0.00 | A | F | Y | 68.00000 | KG | 20160825 | MD | DE | DE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 105940582 | 10594058 | 1 | PS | TASIGNA | NILOTINIB | 1 | Oral | 600 MG, QD | U | 22068 | 600 | MG | QD | ||||||
| 105940582 | 10594058 | 2 | SS | TASIGNA | NILOTINIB | 1 | Oral | 600 MG, QD | U | 22068 | 600 | MG | QD | ||||||
| 105940582 | 10594058 | 3 | SS | TASIGNA | NILOTINIB | 1 | Oral | 600 MG, QD | U | 22068 | 600 | MG | QD | ||||||
| 105940582 | 10594058 | 4 | SS | TASIGNA | NILOTINIB | 1 | Oral | 600 MG, QD | U | 22068 | 600 | MG | QD | ||||||
| 105940582 | 10594058 | 5 | SS | TASIGNA | NILOTINIB | 1 | Oral | 600 MG, QD | U | 22068 | 600 | MG | QD | ||||||
| 105940582 | 10594058 | 6 | SS | TASIGNA | NILOTINIB | 1 | Oral | 600 MG, QD | U | 22068 | 600 | MG | QD | ||||||
| 105940582 | 10594058 | 7 | SS | TASIGNA | NILOTINIB | 1 | Oral | 600 MG, QD | U | 22068 | 600 | MG | QD | ||||||
| 105940582 | 10594058 | 8 | SS | TASIGNA | NILOTINIB | 1 | Oral | 300 MG, QD | U | 22068 | 300 | MG | QD | ||||||
| 105940582 | 10594058 | 9 | SS | TASIGNA | NILOTINIB | 1 | Oral | 450 MG, QD | U | 22068 | 450 | MG | QD | ||||||
| 105940582 | 10594058 | 10 | C | AMITRIPTYLIN | AMITRIPTYLINE | 1 | Unknown | 0 | |||||||||||
| 105940582 | 10594058 | 11 | C | STILNOX | ZOLPIDEM TARTRATE | 1 | Unknown | 0 | |||||||||||
| 105940582 | 10594058 | 12 | C | ATORVASTATIN | ATORVASTATIN | 1 | Unknown | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 105940582 | 10594058 | 1 | Chronic myeloid leukaemia |
| 105940582 | 10594058 | 10 | Product used for unknown indication |
| 105940582 | 10594058 | 11 | Product used for unknown indication |
| 105940582 | 10594058 | 12 | Product used for unknown indication |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 105940582 | 10594058 | Alopecia | |
| 105940582 | 10594058 | Intervertebral disc protrusion |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 105940582 | 10594058 | 1 | 20140610 | 0 | ||
| 105940582 | 10594058 | 2 | 20140701 | 0 | ||
| 105940582 | 10594058 | 3 | 20140730 | 0 | ||
| 105940582 | 10594058 | 4 | 20140916 | 0 | ||
| 105940582 | 10594058 | 5 | 20150107 | 0 | ||
| 105940582 | 10594058 | 6 | 20150708 | 0 | ||
| 105940582 | 10594058 | 7 | 20160113 | 0 | ||
| 105940582 | 10594058 | 8 | 20160515 | 20160525 | 0 | |
| 105940582 | 10594058 | 9 | 20160712 | 0 | ||
| 105940582 | 10594058 | 10 | 20140325 | 0 | ||
| 105940582 | 10594058 | 11 | 20140325 | 0 | ||
| 105940582 | 10594058 | 12 | 20140325 | 0 |